Cytokinetics Inc

CYTK remains under distribution pressure, with price rejecting at the 9- and 20-period EMAs and approaching its rising 200-day SMA. The active Post-Parabola Collapse pattern identifies mean-reversion eligibility, shifting the medium-term bias to bullish despite the short-term downtrend. However, tactical execution remains unfavorable until price can reclaim and accept above the short-term EMAs. Therefore, entries should be deferred ("Stalk") around the 200-day SMA support, awaiting a clear reversal signal.

• ↑Q2'26 myCORSO revenues reached $25.3M with >700 prescribers onboard.
• ↑Achieved ~90% Medicare parity and >50% commercial coverage for myCORSO.
• ↓Q2'26 net loss widened to $198.8M ($1.50/share) from $134.4M.